White paper cover for Pharma R&D Annual Review 2024

In this annual review, we include all drugs in development by pharmaceutical companies, from those at the preclinical stage, through the various stages of clinical testing and regulatory approval, and up to and including launch. Launched drugs are counted, but only if they are still in development for additional indications or markets. Drugs whose development has been terminated, or is complete, are not included.

Business in China is going through a period of uncertainty.
Helen Chen, L.E.K. Consulting

Related resources

Infographic Banner for Pharma R&D Annual Review 2024 Supplement NAS Infograpic
MAY 09, 2024
Infographic
Clinical

Pharma Annual R&D Review 2024 Supplement Infographic: New Active Substances Launched During 2023

Highlights from the Pharma R&D Review 2024 Supplement, a look at new active substances (NASs), drugs launched onto the market for the first time, in 2024.

Citeline Clinical Infographic: A Promising Rebound Selected Insights from the Annual Clinical Trials Roundup: 2024 Edition
OCT 10, 2024
Infographic
Clinical

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery

The rebound in clinical trial starts in 2023 signals a return to form after last year’s decline.

Annual Completed Clinical Trials Report Banner
MAY 22, 2024
Whitepaper
Clinical

Annual Completed Clinical Trials Report

Key insights and results from our annual review of trends in clinical trials completed in 2023, based on Trialtrove data